The paper presented in this issue by O'Shaughnessy et al confirms the linkage of Gordon's syndrome, also called type II pseudo-hypoaldosteronism, with a locus on the long arm of chromosome 17, about 15 cM from the ACE locus. The linkage data were obtained with a single pedigree, which was not the case for the previously reported linkage analysis. 1 The LOD-score value does not reach what is usually admitted as significant, but corresponds to what can be expected from such a pedigree structure.
The fact that linkages were found for this autosomal dominant form of hypertension, to loci on chromosome 17 and 1 has two consequences. The first is to definitively establish its genetic origin and open the way for finding the responsible gene. The second consequence is to show that the syndrome is heterogeneous in its genetic aetiology, but that does not imply in its physiopathology, since the genes could be involved in the same physiological function, either by acting synergistically, or in a gene cascade.
The results from O'Shaughnessy et al go far beyond the elucidation of a monogenic and rare form of hypertension for several reasons. The first reason is because the gene responsible for Gordon's syndrome is still unknown, although the linkage data designates a small region on chromosome 17. This contrasts with the other forms of monogenic hypertension for which the gene identity and function were suspected before the molecular elucidation of the disease. This was the case for Liddle's syndrome for which the epithelial sodium channel was a strong candidate, and the 11␤HSD2 gene for apparent mineralocorticoid excess, two other forms of monogenic hypertension.
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The second reason is because Gordon's syndrome is probably the form of monogenic hypertension which mimics most closely essential hypertension. The blood pressure levels are not very high and the Correspondence: F Soubrier biological phenotype is rather attenuated, composed of fluctuating hyperkalaemia with hyperchloraemic acidosis, and a pronounced beneficial effect of thiazides. This mild phenotype might leave a large proportion of Gordon's syndrome undiagnosed, if hyperkalaemia, the most evident sign, is not recognised. The linkage to chromosome 17 might suggest some tight physiopathological relationships with human essential hypertension, and with rat hereditary hypertension. Indeed, a linkage was found by Julier et al 4 to the same locus on chromosome 17, using a large panel of hypertensive families from France and the UK. It is not possible at this stage to know whether the gene responsible for the linkage data with essential hypertension is the same as the gene pointed out in this region by the linkage with Gordon's syndrome, but the hypothesis is appealing. Julier et al 4 carefully studied this locus on chromosome 17 because this locus is homologous to a rat locus for high blood pressure on rat chromosome 10, found in a cross between SHR/SP and WKY rats. 5, 6 Before further exploring this hypothesis, let us take the example of the role of the factor V gene R506Q mutation in thrombo-phlebitis. 7 This mutation was not recognised until the correct biological test was able to identify this particular cause of thrombophlebitis. 8 The mutation was first recognised in pedigrees with several cases of deep vein thrombosis, before being recognised as a widespread risk factor. Since a large proportion of carriers of this mutation never develop any thrombophlebitis episode, the existence of a putative genetic interacting factor is suspected, in addition to known environmental factors.
Thus, the gene responsible for Gordon's syndrome might represent an unrecognised common cause of rise in blood pressure. Whether the mutations occurring in Gordon's syndrome are identical or of different types than those we might find in essential hypertension is an interesting question.
The discovery of the gene involved in Gordon's syndrome is therefore of major interest, but is also of major difficulty since no described family has the size required for allowing the candidate region to be significantly narrowed.
Even before having found the gene, it would be of invaluable help to define a biological phenotype specific of the disease, through a very accurate study of renal function of these affected subjects. An increased chloride reabsorption was indeed found by different groups on different families, and might represent the major intermediate phenotype of this disease. 9, 10 This phenotype should be carefully researched in essential hypertensives and their families. This could lead to a robust intermediate phenotype, able to stratify essential hypertension according to a biological phenotype, and perhaps to define a subgroup of patients in which the linkage to chromosome 17 locus (or with the chromosome 1 locus) would be stronger.
Finally, genetic research on Gordon's syndrome illustrates that several important genes, involved in renal physiology and blood pressure regulation, and representing very interesting new targets for antihypertensive treatment, remain to be discovered.
